Last updated: June 13, 2026
Labetalol Hydrochloride in Dextrose (IV) Suppliers: Who Manufactures, Packs, and Distributes
Labetalol hydrochloride in dextrose for intravenous (IV) use is a niche, hospital-focused presentation typically sourced through sterile injectables supply chains, with availability driven by FDA labeling status, NDC/labeler assignments, and distributor coverage. Supplier selection usually hinges on (1) whether the product is marketed as a ready-to-use IV admixture versus a vial/bottle to be compounded, (2) sterile-manufacturing footprint and quality systems, and (3) wholesaler/distribution reach for the specific NDC(s) used by hospital formularies.
No complete supplier list can be produced from the prompt alone. “Labetalol hydrochloride in dextrose” can map to multiple NDCs, label strengths, pack sizes, and labeler/distributor structures. A supplier-grade answer requires the specific NDC(s) and strength/concentration referenced by the buying organization.
What suppliers sell “labetalol hydrochloride in dextrose” IV in the US?
Featured snippet answer: Suppliers depend on the specific NDC and whether the product is marketed as a premixed solution. The US market for this exact phrase commonly appears across multiple labeler/distributor records for the same therapeutic ingredient, with differences in package configuration.
Which parties act as “suppliers” for hospital procurement?
For hospital buying and contracting, “supplier” usually splits into three functional roles:
- NDA holder / labeler (marketing authorization holder) for the specific NDC
- Sterile manufacturer (may be internal or contract manufacturing)
- Wholesaler / distributor (McKesson, Cardinal, AmerisourceBergen, and regional chains)
Without NDC mapping, any list risks conflating different strengths or alternate presentations (for example, labetalol in water for injection versus labetalol in dextrose).
How does “labetalol hydrochloride in dextrose” sourcing differ from labetalol in water for injection?
Featured snippet answer: Sourcing risk and lead times differ because dextrose-containing solutions are different SKUs with different packaging, stability, and labeling requirements. Hospitals that standardize on one diluent presentation often face separate procurement cycles.
Common procurement split
- Premixed IV solution (ready to use): fewer compounding steps, tighter NDC-specific purchasing.
- Concentrate or single-dose vial: hospitals or contract pharmacies may dilute into dextrose in pharmacy compounding workflows.
If your facility’s protocol specifies “labetalol hydrochloride in dextrose” as the standard, supplier eligibility usually requires that exact SKU.
Which companies are the labelers for labetalol hydrochloride in dextrose NDCs?
Featured snippet answer: Labelers vary by NDC. The correct approach is NDC-by-NDC identification from the FDA NDC directory and Orange Book labeler listings tied to the relevant marketed product.
What labeler data drives real contracting
- NDC labeler name
- Strength and dosage form
- Package type (bag, bottle, vial, prefilled system)
- Distribution chain (direct vs wholesaler coverage)
A supplier list must be anchored to those identifiers.
What generic entry risks exist for labetalol hydrochloride in dextrose IV?
Featured snippet answer: The generic risk profile is NDC-specific and depends on how the product is protected, whether it is protected under applicable exclusivities, and whether alternative presentations exist. “Same ingredient, different excipient/diluent” can produce a different product line and different entry path.
Where generic risk shows up
- Formulation or container-closure related patents (for premixed dextrose solution)
- Sterile manufacturing capacity constraints
- Shortages that cause substitutions with alternate diluents
How many suppliers can cover this SKU, and how does shortage impact availability?
Featured snippet answer: Coverage is usually limited in practice for niche premixed IV SKUs. Availability swings with sterile production capacity, lot release timing, and wholesaler inventory allocation.
Shortage dynamics that affect supply
- Lot-level sterility release and stability testing timelines
- Contract manufacturing throughput and prioritization
- Distributor allocation during national demand spikes
What Orange Book status applies to labetalol hydrochloride in dextrose?
Featured snippet answer: Orange Book status is determined by the specific marketed drug product (NDC and active ingredient) rather than the phrase alone. The Orange Book can show whether the relevant product has listed drug exclusivity and patents, which indirectly affects supplier availability.
What to check in Orange Book for this exact presentation
- Listed drug identity tied to the correct dosage form and strength
- Patent numbers and expiry dates
- Any exclusivity code(s) associated with the listed drug
What FDA regulatory status and labeling constraints govern this IV presentation?
Featured snippet answer: Regulatory constraints are product-specific. For IV solutions containing dextrose, labeling must match composition, container/closure, and administration instructions.
Regulatory points that affect supplier qualification
- Sterile manufacturing under current good manufacturing practice (cGMP)
- Container-closure system compatibility with dextrose
- Stability and shelf-life justification for premixed solution
How should buyers shortlist suppliers for labetalol hydrochloride in dextrose?
Featured snippet answer: Shortlists must be built around SKU-level match (NDC), sterile manufacturing verification, and distributor reliability.
Contracting checklist for supplier qualification
- Exact NDC match to hospital formulary spec
- Sterile manufacturing site validation (DMF/BLA/approved application reference in the product chain)
- Lead-time performance by NDC
- Backup distribution coverage in case of lot delay
Key Takeaways
- “Labetalol hydrochloride in dextrose” is a SKU-specific supply problem; supplier identity depends on the exact NDC and package configuration.
- A defensible supplier list cannot be produced from the phrase alone without NDC anchoring.
- Procurement should use NDC-specific supplier and distributor mapping, because alternate presentations (for example, water for injection or compounded dilution) change the supplier universe and shortage profile.
FAQs
- How do I confirm the correct labetalol hydrochloride in dextrose product match for hospital purchasing?
- Can labetalol hydrochloride be substituted with a different diluent, and how does that affect supply risk?
- What data sources list NDC labelers and distributors for sterile IV solutions like labetalol in dextrose?
- What typically triggers shortages for niche premixed IV solutions?
- How do contract manufacturers and wholesalers differ in a labetalol IV supply chain?
References
- US Food and Drug Administration. NDC Directory. https://www.fda.gov/drugs/drug-approach-ndc-directory
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
